Off-label use of stents: Bare-metal versus drug-eluting stents

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 8, 2008, Pages 1095-1106

  Girod, John P ^a   Mulukutla, Surech R ^a   Marroquin, Oscar C ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Bare metal stent; Drug eluting stent; Efficacy; Off label; Safety

Indexed keywords

PACLITAXEL; RAPAMYCIN;

BARE METAL STENT; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG ELUTING STENT; EQUIPMENT DESIGN; HEART EJECTION FRACTION; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; MORTALITY; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; RISK FACTOR; SAFETY; STROKE; THROMBOSIS; VEIN GRAFT DISEASE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; CORONARY RESTENOSIS; CORONARY VESSELS; DRUG LABELING; DRUG-ELUTING STENTS; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; RISK FACTORS; SAFETY; STENTS; THROMBOSIS;

EID: 55349118517     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.8.1095     Document Type: Review

References (86)

1. Serruys PW, de Jaegere P, Kiemeneij F et al.; Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N. Engl. J. Med. 331, 489-495 (1994).
2. Fischman DL, Leon MB, Baim DS et al.; Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N. Engl. J. Med. 331, 496-501 (1994).
3. Colombo A, Hall P, Nakamura S et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 91, 1676-1688 (1995).
4. Leon MB, Baim DS, Popma JJ et al.; Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N. Engl. J. Med. 339, 1665-1671 (1998).
5. Holmes DR Jr, Teirstein P, Satler L et al. Sirolimus-eluting stents versus vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA 295, 1264-1273 (2006).
6. Stone GW, Ellis SG, O'Shaughnessy CD et al. Paclitaxel-eluting stents versus vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA 295, 1253-1263 (2006).
7. Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Fngl. J. Med. 346, 1773-1780 (2002).
8. Colombo A, Drzewiecki J, Banning A et al. Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108, 788-794 (2003).
9. Grube E, Silber S, Hauptmann KE et al. TAXUS I: six-and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107, 38-42 (2003).
10. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349, 1315-1323 (2003).
11. Schofer J, Schluter M, Gershlick AH et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362, 1093-1099 (2003).
12. Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 350, 221-231 (2004).
13. Dawkins KD, Grube E, Guagliumi G et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 112, 3306-3313 (2005).
14. Stone GW, Ellis SG, Cannon L et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 294, 1215-1223 (2005).
15. Weisz G, Leon MB, Holmes DR Jr et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de novo Native Coronary Lesions (SIRIUS) trial. J. Am. Coll. Cardiol. 47, 1350-1355 (2006).
16. Maisel WH. Unanswered questions - drug-eluting stents and the risk of late thrombosis. N. Engl. J. Med. 356, 981-984 (2007).
17. Muni NI, Gross TP. Problems with drug-eluting coronary stents - the US FDA perspective. N. Engl. J. Med. 351, 1593-1595 (2004).
18. Grines CL. Off-label use of drug-eluting stents putting it in perspective. J. Am. Coll. Cardiol. 51, 615-617 (2008).
19. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 115, 1440-1455 (2007).
20. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur. Heart J. 27, 2784-2814 (2006).
21. Farb A, Boam AB. Stent thrombosis redux - the US FDA perspective. N. Engl. J. Med. 356, 984-987 (2007).
22. Maisel WH, Laskey WK. Cardiology patient page. Drug-eluting stents. Circulation 115, e426-e427 (2007).
23. Spaulding AC, Allen SA, Stone A. Mortality after release from prison. N. Engl. J. Med. 356, 1786-1787 (2007).
24. Stone GW, Moses JW, Ellis SG et al. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents. N. Engl. J. Med. 356, 998-1008 (2007).
25. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino, R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N. Engl. J. Med. 356, 1020-1029 (2007).
26. Kastrati A, Mehilli J, Pache J et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N. Engl. J. Med. 356, 1030-1039 (2007).
27. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-cluting scents versus bare-metal stents in Sweden. N. Engl. J. Med. 356, 1009-1019 (2007).
28. Tu JV, Bowen J, Chiu M et al. Effectiveness and safety of drug-eluting stents in Ontario, N. Engl. J. Med. 357, 1393-1402 (2007).
29. Jensen LO, Maeng M, Kaltoft A et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J. Am. Coll. Cardiol. 50, 463-470 (2007).
30. Marzocchi A, Saia F, Piovaccari G et al. Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. Circulation 115, 3181-3188 (2007).
31. Stettler C, Wandel S, Allemann S et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370, 937-948 (2007).
32. Rao SV, Shaw RE, Brindis RG, Klein LW, Weintraub WS, Peterson ED. On-versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry (NCDRI). Am. J. Cardiol. 97, 1478-1481 (2006).
33. Beohar N, Davidson CJ, Kip KE et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 297, 1992-2000 (2007).
34. Win HK, Caldera AE, Maresh K et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297, 2001-2009 (2007).
35. Qasim A, Cosgrave J, Latib A, Colombo A. Long-term follow-up of drug-eluting stents when inserted for on-and off-label indications. Am. J. Cardiol. 100, 1619-1624 (2007).
36. Marroquin OC, Selzer F, Mulukutla SR et al. A comparison of bare-metal and drug-eluting stents for off-label indications. N. Engl. J. Med. 358, 342-352 (2008).
37. Applegate RJ, Sacrinty MT, Kutcher MA et al. "Off-label" stent therapy 2-year comparison of drug-eluting versus bare-metal scents. J. Am. Coll. Cardiol. 51, 607-614 (2008).
38. Roy P, Buch AN, Javaid A et al. Impact of "off-label" utilization of drug-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention. Am. J. Cardiol. 101, 293-299 (2008).
39. Pfisterer M, Brunner-La Rocca HP, Buser PT et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol. 48, 2584-2591 (2006).
40. Fischell TA, Holmes DR Jr. Late DES thrombosis: a lot of smoke, very little fire? Catheter Cardiovasc. Interv. 69, 609-615 (2007).
41. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a benign clinical entity. Am. Heart J. 151, 1260-1264 (2006).
42. Kastrati A, Mehilli J, von Beckerath N et al. Sirolimus-eluting stent or paclitaxeleluting stent versus balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 293, 165-171 (2005).
43. Ge L, Iakovou I, Sangiorgi GM et al. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J. Am. Coll. Cardiol. 45, 989-994 (2005).
44. Minutello RM, Bhagan S, Sharma A et al. Long-term clinical benefit of sirolimus-eluting stents compared with bare metal stents in the treatment of saphenous vein graft disease. J. Interv. Cardiol. 20, 458-465 (2007).
45. Lee MS, Shah AP, Aragon J et al. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc. Interv. 66, 507-511 (2005).
46. Vignali L, Saia F, Manari A et al. Long-term outcomes with drug-eluting stents versus bare metal stents in the treatment of saphenous vein graft disease (results from the REgistro Regionale AngiopLastiche Emilia-Romagna registry). Am. J. Cardiol. 101, 947-952 (2008).
47. Vermeersch P, Agostoni P, Verheye S et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J. Am. Coll. Cardiol. 48, 2423-2431 (2006).
48. Vermeersch P, Agostoni P, Verheye S et al. Increased late mortality after sirolimus-eluting stents versus bare-meral stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J. Am. Coll. Cardiol. 50, 261-267 (2007).
49. Ramana RK, Ronan A, Cohoon K et al. Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease. Catheter Cardiovasc. Interv. 71, 886-893 (2008).
50. Ellis SG, Savage M, Fischman D et al. Restenosis after placement of Palmaz-Schatz stents in native coronary arteries. Initial results of a multicenter experience. Circulation 86, 1836-1844 (1992).
51. Kastrati A, Elezi S, Dirschinger J, Hadamitzky M, Neumann FJ, Schomig A. Influence of lesion length on restenosis after coronary stent placement. Am. J. Cardiol. 83, 1617-1622 (1999).
52. Kereiakes DJ, Wang H, Popma JJ et al. Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials. J. Am. Coll. Cardiol. 48, 21-31 (2006).
53. Kim YH, Park SW, Lee CW et al. Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions. Catheter Cardiovasc. Interv. 67, 181-187 (2006).
54. Shishehbor MH, Amini R, Raymond RE et al. Safety and efficacy of overlapping sirolimus-eluting versus paclitaxel-eluting stents. Am. Heart J. 155, 1075-1080 (2008).
55. Tsuchiya Y, Lansky AJ, Costa RA et al. Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am. J. Cardiol. 98, 464-469 (2006).
56. Ardissino D, Cavallini C, Bramucci E et al. Sirolimus-eluting versus uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 292, 2727-2734 (2004).
57. Steigen TK, Maeng M, Wiseth R et al. Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation Study. Circulation 114, 1955-1961 (2006).
58. Colombo A, Moses JW, Morice MC et al. Randomized study to evaluate sirolimus-eluting scents implanted at coronary bifurcation lesions. Circulation 109, 1244-1249 (2004).
59. Pan M, de Lezo JS, Medina A et al. Rapamycin-eluting stents for the treatment of bifurcated coronary lesions: a randomized comparison of a simple versus complex strategy. Am. Heart J. 148, 857-864 (2004).
60. Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293, 2126-2130 (2005).
61. Kuchulakanti PK, Chu WW, Torguson R et al. Correlates and long-term outcomes of an giographically proven stent thrombosis with sirolimus-and paclitaxel-eluting stents. Circulation 113, 1108-1113 (2006).
62. Thuesen L, Kelbaek H, Klovgaard L et al. Comparison of sirolimus-eluting and bare metal scents in coronary bifurcation lesions: subgroup analysis of the Scenting Coronary Arteries in Non-Stress/ Benestent Disease Trial (SCANDSTENT). Am. Heart J. 152, 1140-1145 (2006).
63. Iakovou I, Ge L, Michev I et al. Clinical and angiographic outcome after sirolimus-eluting stent implantation in aorto-ostial lesions. J. Am. Coll. Cardiol. 44, 967-971 (2004).
64. Seung KB, Kim YH, Park DW et al. Effectiveness of sirolimus-eluting stent implantation for the treatment of ostial left anterior descending artery stenosis with intravascular ultrasound guidance. J. Am. Coll. Cardiol. 46, 787-792 (2005).
65. Kelbaek H, Thuesen L, Helqvist S et al. The Stenting Coronary Arteries in Non-stress/Benestent Disease (SCANDSTENT) trial. J. Am. Coll. Cardiol. 47, 449-455 (2006).
66. Chairman BR, Fisher LD, Bourassa MG et al. Effect of coronary bypass surgery on survival patterns in subsets of patients with left main coronary artery disease. Report of the Collaborative Study in Coronary Artery Surgery (CASS). Am. J. Cardiol. 48, 765-777 (1981).
67. Taggart DP, Kaul S, Boden WE et al. Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery. J. Am. Coll. Cardiol. 51, 885-892 (2008).
68. Tan WA, Tamai H, Park SJ et al. Long-term clinical outcomes after unprotected left main trunk percutaneous revascularization in 279 patients. Circulation 104, 1609-1614 (2001).
69. Price MJ, Cristea E, Sawhney N et al. Serial angiographic follow-up of sirolimus-eluting stents for unprotected left main coronary artery revascularization. J. Am. Coll. Cardiol. 47, 871-877 (2006).
70. Valgimigli M, Malagutti P, Rodriguez-Granillo GA et al. Discal left main coronary disease is a major predictor of outcome in patients undergoing percutaneous intervention in the drug-eluting stent era: an integrated clinical and angiographic analysis based on the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) registries. J. Am. Coll. Cardiol. 47, 1530-1537 (2006).
71. Chieffo A, Park SJ, Valgimigli M et al. Favorable long-term outcome after drug-eluting stent implantation in nonbifurcation lesions that involve unprotected left main coronary artery: a multicenter registry. Circulation 116, 158-162 (2007).
72. Erglis A, Narbute I, Kumsars I et al. A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unprotected left main coronary artery stenosis. J. Am. Coll. Cardiol. 50, 491-497 (2007).
73. Park SJ, Kim YH, Lee BK et al. Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. J. Am. Coll. Cardiol. 45, 351-356 (2005).
74. Valgimigli M, van Mieghem CA, Ong AT et al. Short-and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). Circulation 111, 1383-1389 (2005).
75. Seung KB, Park DW, Kim YH et al. Stents versus coronary-artery bypass grafting for left main coronary artery disease. N. Engl. J. Med. 358, 1781-1792 (2008).
76. Ong AT, Serruys PW, Mohr FW et al. The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. Am. Heart J. 151, 1194-1204 (2006).
77. Rahel BM, Suttorp, MJ, Laarman GJ et al. Primary stenting of occluded native coronary arteries: final results of the Primary Scenting of Occluded Native Coronary Arteries (PRISON) study. Am. Heart J. 147, e22 (2004).
78. Suttorp MJ, Laarman GJ, Rahel BM et al. Primary Scenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation 114, 921-928 (2006).
79. Kelbaek H, Helqvist S, Thuesen L et al. Sirolimus versus bare metal stent implantation in patients with total coronary occlusions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/ Benestent Disease (SCANDSTENT) trial. Am. Heart J. 152, 882-886 (2006).
80. Newell MC, Henry CR, Sigakis CJ et al. Comparison of safety and efficacy of sirolimus-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction. Am. J. Cardiol. 97, 1299-1302 (2006).
81. Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369, 667-678 (2007).
82. Spaulding q, Henry P, Teiger E et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N. Engl. J. Med. 355, 1093-1104 (2006).
83. Laarman GJ, Suttorp MJ, Dirksen MT et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N. Engl. J. Med. 355, 1105-1113 (2006).
84. Menichelli M, Parma A, Pucci E et al. Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J. Am. Coll. Cardiol. 49, 1924-1930 (2007).
85. Kastrati A, Dibra A, Spaulding C et al. Meta-analysis of randomized trials on drug-eluting stents versus. bare-metal stents in patients with acute myocardial infarction. Eur. Heart J. 28, 2706-2713 (2007).
86. Mehran R, Brodie B, Cox DA et al. The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONSAMI) Trial: study design and rationale. Am. Heart J. 156, 44-56 (2008).